LRRK2 and Parkinson disease: Qing et al. successfully reduced the incidence of familial and sporadic PD by editing mutant LRRK2 using CRISPR/Cas9, thereby presenting a potential avenue for treating both forms of PD, they performed unbiased detection of the top 8 potential off-target sites predicted by the COD algorithm, and Sanger sequencing analysis showed no off-target indels (Qing et al., 2017).